* [PROSEVA](https://www.nejm.org/doi/10.1056/NEJMoa1214103) (2013)
	* 474 Europeans with ARDS (PF <150mmHg), intubated for <36 hours at inclusion
	* Multicentre, assessor-blinded, RCT
	* 456 patients gives 90% power for 15% ARR from control mortality of 60%
	* Randomised to proning vs. supine
		* Proning\
		16 consecutive hours for 28 days, or until improvement.
		* Standardised ventilation and weaning strategy
	* Significant â†“ mortality (16% vs. 33%, OR 0.42 (0.26-0.66), NNT 6) in proning group
	* Over 2000 patients were not screened

:::column-margin
![](/resources/proseva.png)
:::

:::column-margin
PROSEVA was the definitive trial on proning, and no treat
:::